Fluzoparib Neoadjuvant Therapy for Ovarian Cancer

This study is an interventional, single-arm, open-label clinical trial. To evaluate the safety and efficacy of Fluzoparib as neoadjuvant therapy in patients with FIGO stage III and IV , BRCA mutations or HRD positive epithelial ovarian cancer who cannot achieve R0 surgery as assessed by imaging (Suidan's CT score) or laparoscopy (Fagotti score), or cannot tolerate surgery.

Trial Details

NCT ID

NCT06541314

Phase

PHASE2

Sponsor

Qilu Hospital of Shandong University

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

Fluzoparib

Locations (sample)

Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

Female patients aged 18-75 years.
Biopsies obtained via open surgery, laparoscopic surgery, or needle biopsy, confirmed by professional pathologists as high-grade serous or endometr…
Presence of BRCA1/2 mutation or HRD positivity confirmed in tissue or blood samples by the designated testing institution of the study center.
Before any trial procedures begin, an informed consent form must be signed according to the principle of informed consent and filed at the study ce…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →